Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.

Psoriatic Arthritis References

  1. Gossec L, Smolen JS, Gaujoux-Viala C, et al; European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012 Jan;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350. PMID: 21953336
  2. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermat. 2008 May;58(5):851-864. doi: 10.1016/j.jaad.2008.02.040. PMID: 18423261
  3. Kyle S, Chandler D, Griffiths M, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology. 2005 Mar;44(3):390-397. PMID: 15695305
  4. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009 Sep;68(9):1387-1394. doi: 10.1136/ard.2008.094946. PMID: 18952643
  5. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78. PMID: 4581554
  6. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-2673. PMID: 16871531
  7. Voorhees AV, Feldman SR, Koo JYM, et al. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. The National Psoriasis Foundation; 2009
  8. MedWorm
  9. MedWorm
  10. Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. SIGN. 2010. Accessed 17 Jul 2011
  11. National Institute for Health and Care Excellence. Golimumab for the treatment of psoriatic arthritis. NICE. 2011
  12. Coates L, Tillett W, Chandler P, et al. The 2012 British Society for Rheumatology guidelines for the treatment of psoriatic arthritis with biologicals. 2012. Accessed 24 Jul 2013
  13. National Institute for Health and Care Excellence. Review of TA199; Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (includes a review of NICE technology appraisal guidance 104 and 125), and TA220; Golimumab for the treatment of psoriatic arthritis. NICE. 2013
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 20 Oct 2020
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.